Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cytek Biosciences Inc (CTKB)

152 + Investors. Track Smart Money conviction in CTKB. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -9
Streak
1Q ▼
Buyers last Q
43%

Smart Money Signals — CTKB

Based on 153 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their CTKB positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 94% of 3.0Y peak

94% of all-time peak
153 funds currently hold this stock — 94% of the 3.0-year high of 162 funds (reached 2026 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding CTKB is almost the same as a year ago (+0 funds, +0% change). No significant rush to buy or sell — institutional backing is holding steady.
🟠

More sellers than buyers — 43% buying

75 buying101 selling
Last quarter: 101 funds reduced or exited vs 75 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new CTKB position: 23 → 22 → 24 → 30. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 37% medium ■ 16% new
73 out of 153 hedge funds have held CTKB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

23 → 23 → 22 → 24 → 30 new funds/Q
New funds entering each quarter: 23 → 22 → 24 → 30. A growing number of institutions are discovering CTKB each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 58% veterans vs 20% newcomers

■ 58% veterans ■ 22% 1-2yr ■ 20% new
Entry-cohort mix of 153 holders: 89 (58%) are 2+ year veterans, 33 entered 1–2 years ago, and 31 (20%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 52% AUM from top-100 funds

52% from top-100 AUM funds
43 of 153 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in CTKB. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.5
out of 10
Low Exit Risk
Exit risk score 3.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CTKB

In 2026 Q2, 75 hedge funds were net buyers of CTKB (30 opened a new position, 45 added to an existing one), while 101 reduced or exited (62 trimmed, 39 sold completely) — a 43% buyer ratio, indicating roughly balanced activity. 52% of total institutional value in CTKB is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -9 funds (more exits than new entries). Total institutional holders: 153.

Hedge Fund Ownership: CTKB

How many hedge funds hold CTKB — quarterly history vs. share price
Quarterly hedge fund ownership of CTKB vs. share price

Market Analysis: CTKB

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CTKB

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cytek Biosciences Inc (CTKB) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CTKB has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 60d ago
CTKB
+4.3%
XLV
+8.1%

CTKB outperformed XLV by -3.8% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 15d ago
CTKB
-1.5%
XLV
+2.5%

Since the filing became public, CTKB outperformed XLV by -4.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

8 top-rated funds 1 high-conviction
Consensus
4.1
/ 10
breadth
×
Elite
0.9
/ 10
conviction
Hedge Fund Positioning: CTKB
152 + Investors

Track Smart Money conviction in CTKB. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 152 162 -6.17%
13F Shares 81M 85M -3.88%
Total Value $353M $366M -3.49%
New Positions 30 24 +6
Increased Positions 44 65 -21
Closed Positions 40 14 +26
Reduced Positions 62 52 +10
Total Calls 0 1 -100.0%
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: CTKB

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

152 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CTKB. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CTKB holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Topline Capital Management, LLC 7.22% 6,283,450 $27.8M
2 Hhlr Advisors, LTD. 3.54% 6,657,030 $29.5M
3 EntryPoint Capital, LLC 0.38% 99,036 $553K
4 R Squared Ltd 0.08% 35,412 $157K
5 Royce & Associates LP 0.07% 2,081,579 $9.2M
6 Numerai GP LLC 0.06% 159,465 $706K
7 CenterBook Partners LP 0.03% 149,180 $661K
8 Boston Partners 0.03% 7,660,943 $33.9M
9 PDT Partners, LLC 0.02% 86,869 $385K
10 Aigen Investment Management, LP 0.02% 14,029 $62K
11 Y-Intercept (Hong Kong) Ltd 0.02% 193,128 $856K
12 Catalyst Funds Management Pty Ltd 0.02% 62,500 $277K
13 Millennium Management LLC 0.01% 9,338,010 $41.4M
14 Prelude Capital Management, LLC 0.01% 45,259 $200K
15 Axq Capital, LP 0.01% 28,299 $125K
16 Aquatic Capital Management LLC 0.01% 76,762 $340K
17 Campbell & CO Investment Adviser LLC 0.01% 39,333 $174K
18 XTX Topco Ltd 0.01% 142,723 $632K
19 Hrt Financial LP 0.01% 997,769 $4.4M
20 Jain Global LLC 0.01% 411,465 $1.8M
21 Russell Investments Group, Ltd. 0.01% 1,511,315 $6.7M
22 Tudor Investment Corp Et Al 0.01% 837,913 $3.7M
23 Two Sigma Securities, LLC 0.00% 11,180 $50K
24 Renaissance Technologies LLC 0.00% 661,300 $2.9M
25 Jacobs Levy Equity Management, Inc 0.00% 241,581 $1.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cytek Biosciences Inc (CTKB)

What does the Smart Money Trend signal show for CTKB?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CTKB positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CTKB?

More sellers than buyers — 43% buying: Last quarter: 101 funds reduced or exited vs 75 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for CTKB holders?

Elite ownership — 52% AUM from top-100 funds: 43 of 153 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in CTKB. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CTKB?

48% of holders stayed for 2+ years: 73 out of 153 hedge funds have held CTKB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cytek Biosciences Inc (CTKB) following the 2026 Q2 hedge fund 13F filings?

As of today, CTKB has moved -1.5% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.5% for the XLV sector ETF — an outperformance of -4.0%. Since the quarter end (June 30, 2026), CTKB has gained +4.3% vs +8.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →